Literature DB >> 26932689

Effect of genotype on the severity and volume progression of polycystic liver disease in autosomal dominant polycystic kidney disease.

Fouad T Chebib1, Yeonsoon Jung2, Christina M Heyer1, Maria V Irazabal1, Marie C Hogan1, Peter C Harris1, Vicente E Torres1, Ziad M El-Zoghby1.   

Abstract

BACKGROUND: The autosomal dominant polycystic kidney disease (APDKD) genotype influences renal phenotype severity but its effect on polycystic liver disease (PLD) is unknown. Here we analyzed the influence of genotype on liver phenotype severity.
METHODS: Clinical data were retrieved from electronic records of patients who were mutation screened with the available liver imaging (n = 434). Liver volumes were measured by stereology (axial or coronal images) and adjusted to height (HtLV).
RESULTS: Among the patients included, 221 (50.9%) had truncating PKD1 (PKD1-T), 141 (32.5%) nontruncating PKD1 (PKD1-NT) and 72 (16.6%) PKD2 mutations. Compared with PKD1-NT and PKD2, patients with PKD1-T had greater height-adjusted total kidney volumes (799 versus 610 and 549 mL/m; P < 0.001). HtLV was not different (1042, 1095 and 1058 mL/m; P = 0.64) between the three groups, but females had greater HtLVs compared with males (1114 versus 1015 mL/m; P < 0.001). Annualized median liver growth rates were 1.68, 1.5 and 1.24% for PKD1-T, PKD1-NT and PKD2 mutations, respectively (P = 0.49), and remained unaffected by the ADPKD genotype when adjusted for age, gender and baseline HtLV. Females <48 years of age had higher annualized growth rates compared with those who were older (2.65 versus 0.09%; P < 0.001). After age 48 years, 58% of females with severe PLD had regression of HtLV, while HtLV continued to increase in males.
CONCLUSIONS: In contrast to the renal phenotype, the ADPKD genotype was not associated with the severity or growth rate of PLD in ADKPD patients. This finding, along with gender influence, indicates that modifiers beyond the disease gene significantly influence the liver phenotype.
© The Author 2016. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Entities:  

Keywords:  ADPKD; PLD; genotype–phenotype; polycystic liver

Mesh:

Substances:

Year:  2016        PMID: 26932689      PMCID: PMC4876970          DOI: 10.1093/ndt/gfw008

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  30 in total

Review 1.  Autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Peter C Harris; Yves Pirson
Journal:  Lancet       Date:  2007-04-14       Impact factor: 79.321

2.  Type of PKD1 mutation influences renal outcome in ADPKD.

Authors:  Emilie Cornec-Le Gall; Marie-Pierre Audrézet; Jian-Min Chen; Maryvonne Hourmant; Marie-Pascale Morin; Régine Perrichot; Christophe Charasse; Bassem Whebe; Eric Renaudineau; Philippe Jousset; Marie-Paule Guillodo; Anne Grall-Jezequel; Philippe Saliou; Claude Férec; Yannick Le Meur
Journal:  J Am Soc Nephrol       Date:  2013-02-21       Impact factor: 10.121

Review 3.  Hepatic cysts in autosomal dominant polycystic kidney disease.

Authors:  G T Everson
Journal:  Mayo Clin Proc       Date:  1990-07       Impact factor: 7.616

4.  Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases.

Authors:  Loes Van Keimpema; Daan B De Koning; Bart Van Hoek; Aad P Van Den Berg; Martijn G H Van Oijen; Robert A De Man; Frederik Nevens; Joost P H Drenth
Journal:  Liver Int       Date:  2011-01       Impact factor: 5.828

5.  Germline mutations in PRKCSH are associated with autosomal dominant polycystic liver disease.

Authors:  Joost P H Drenth; Rene H M te Morsche; Renate Smink; Juan S Bonifacino; Jan B M J Jansen
Journal:  Nat Genet       Date:  2003-02-10       Impact factor: 38.330

6.  Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity.

Authors:  Katharina Hopp; Christopher J Ward; Cynthia J Hommerding; Samih H Nasr; Han-Fang Tuan; Vladimir G Gainullin; Sandro Rossetti; Vicente E Torres; Peter C Harris
Journal:  J Clin Invest       Date:  2012-10-15       Impact factor: 14.808

7.  Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.

Authors:  Loes van Keimpema; Frederik Nevens; Ragna Vanslembrouck; Martijn G H van Oijen; Aswin L Hoffmann; Helena M Dekker; Robert A de Man; Joost P H Drenth
Journal:  Gastroenterology       Date:  2009-07-29       Impact factor: 22.682

8.  Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort.

Authors:  Kyongtae T Bae; Fang Zhu; Arlene B Chapman; Vicente E Torres; Jared J Grantham; Lisa M Guay-Woodford; Deborah A Baumgarten; Bernard F King; Louis H Wetzel; Philip J Kenney; Marijn E Brummer; William M Bennett; Saulo Klahr; Catherine M Meyers; Xiaoling Zhang; Paul A Thompson; J Philip Miller
Journal:  Clin J Am Soc Nephrol       Date:  2005-10-26       Impact factor: 8.237

9.  Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Christina M Heyer; Jamie L Sundsbak; Kaleab Z Abebe; Arlene B Chapman; Vicente E Torres; Jared J Grantham; Kyongtae T Bae; Robert W Schrier; Ronald D Perrone; William E Braun; Theodore I Steinman; Michal Mrug; Alan S L Yu; Godela Brosnahan; Katharina Hopp; Maria V Irazabal; William M Bennett; Michael F Flessner; Charity G Moore; Douglas Landsittel; Peter C Harris
Journal:  J Am Soc Nephrol       Date:  2016-01-28       Impact factor: 10.121

10.  Clinical profile of autosomal dominant polycystic liver disease.

Authors:  Qi Qian; Airong Li; Bernard F King; Patrick S Kamath; Donna J Lager; John Huston; Clarence Shub; Sonia Davila; Stefan Somlo; Vicente E Torres
Journal:  Hepatology       Date:  2003-01       Impact factor: 17.425

View more
  23 in total

1.  Detection and characterization of mosaicism in autosomal dominant polycystic kidney disease.

Authors:  Katharina Hopp; Emilie Cornec-Le Gall; Sarah R Senum; Iris B A W Te Paske; Sonam Raj; Sravanthi Lavu; Saurabh Baheti; Marie E Edwards; Charles D Madsen; Christina M Heyer; Albert C M Ong; Kyongtae T Bae; Richard Fatica; Theodore I Steinman; Arlene B Chapman; Berenice Gitomer; Ronald D Perrone; Frederic F Rahbari-Oskoui; Vicente E Torres; Peter C Harris
Journal:  Kidney Int       Date:  2019-10-09       Impact factor: 10.612

2.  Outcomes and Durability of Hepatic Reduction after Combined Partial Hepatectomy and Cyst Fenestration for Massive Polycystic Liver Disease.

Authors:  Fouad T Chebib; Amber Harmon; Maria V Irazabal Mira; Yeon Soon Jung; Marie E Edwards; Marie C Hogan; Patrick S Kamath; Vicente E Torres; David M Nagorney
Journal:  J Am Coll Surg       Date:  2016-01-14       Impact factor: 6.113

Review 3.  Genetic Complexity of Autosomal Dominant Polycystic Kidney and Liver Diseases.

Authors:  Emilie Cornec-Le Gall; Vicente E Torres; Peter C Harris
Journal:  J Am Soc Nephrol       Date:  2017-10-16       Impact factor: 10.121

Review 4.  Polycystic kidney disease.

Authors:  Carsten Bergmann; Lisa M Guay-Woodford; Peter C Harris; Shigeo Horie; Dorien J M Peters; Vicente E Torres
Journal:  Nat Rev Dis Primers       Date:  2018-12-06       Impact factor: 52.329

5.  PKD2-Related Autosomal Dominant Polycystic Kidney Disease: Prevalence, Clinical Presentation, Mutation Spectrum, and Prognosis.

Authors:  Emilie Cornec-Le Gall; Marie-Pierre Audrézet; Eric Renaudineau; Maryvonne Hourmant; Christophe Charasse; Eric Michez; Thierry Frouget; Cécile Vigneau; Jacques Dantal; Pascale Siohan; Hélène Longuet; Philippe Gatault; Laure Ecotière; Frank Bridoux; Lise Mandart; Catherine Hanrotel-Saliou; Corina Stanescu; Pascale Depraetre; Sophie Gie; Michiel Massad; Aude Kersalé; Guillaume Séret; Jean-François Augusto; Philippe Saliou; Sandrine Maestri; Jian-Min Chen; Peter C Harris; Claude Férec; Yannick Le Meur
Journal:  Am J Kidney Dis       Date:  2017-03-27       Impact factor: 8.860

6.  Tamoxifen for the treatment of polycystic liver disease: A case report.

Authors:  Sophie E Aapkes; Lucas H P Bernts; M van den Berg; Ron T Gansevoort; Joost P H Drenth
Journal:  Medicine (Baltimore)       Date:  2021-08-13       Impact factor: 1.817

Review 7.  Polycystic Liver Disease: Pathophysiology, Diagnosis and Treatment.

Authors:  Luiz Fernando Norcia; Erika Mayumi Watanabe; Pedro Tadao Hamamoto Filho; Claudia Nishida Hasimoto; Leonardo Pelafsky; Walmar Kerche de Oliveira; Ligia Yukie Sassaki
Journal:  Hepat Med       Date:  2022-09-29

8.  Gα12 is required for renal cystogenesis induced by Pkd1 inactivation.

Authors:  Yong Wu; Jen X Xu; Wassim El-Jouni; Tzongshi Lu; Suyan Li; Qingyi Wang; Mei Tran; Wanfeng Yu; Maoqing Wu; Ivan E Barrera; Joseph V Bonventre; Jing Zhou; Bradley M Denker; Tianqing Kong
Journal:  J Cell Sci       Date:  2016-08-05       Impact factor: 5.285

9.  Mutations in GANAB, Encoding the Glucosidase IIα Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease.

Authors:  Binu Porath; Vladimir G Gainullin; Emilie Cornec-Le Gall; Elizabeth K Dillinger; Christina M Heyer; Katharina Hopp; Marie E Edwards; Charles D Madsen; Sarah R Mauritz; Carly J Banks; Saurabh Baheti; Bharathi Reddy; José Ignacio Herrero; Jesús M Bañales; Marie C Hogan; Velibor Tasic; Terry J Watnick; Arlene B Chapman; Cécile Vigneau; Frédéric Lavainne; Marie-Pierre Audrézet; Claude Ferec; Yannick Le Meur; Vicente E Torres; Peter C Harris
Journal:  Am J Hum Genet       Date:  2016-06-02       Impact factor: 11.025

Review 10.  Clinical and genetic characteristics of Korean autosomal dominant polycystic kidney disease patients.

Authors:  Yun Kyu Oh; Hayne Cho Park; Hyunjin Ryu; Yong-Chul Kim; Kook-Hwan Oh
Journal:  Korean J Intern Med       Date:  2021-07-01       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.